Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial

Table 4 Univariate analysis of the clinical factors influencing the efficacy of eradication therapy n (%)

Variable	Sequential therapy	P value	Hybrid therapy	P value
Resistance (n = 124)	n = 59		n = 65
Metronidazole		0.22		0.74
Susceptible	32 (84.2)		37 (94.9)
Resistant	14 (66.7)		25 (96.1)
Clarithromycin		0.73		0.51
Susceptible	37 (77.1)		54 (94.7)
Resistant	9 (81.8)		8 (100)
Tetracycline		0.59		NA
Susceptible	45 (77.6)		62 (95.4)
Resistant	1 (100)
Levofloxacin		0.46		0.45
Susceptible	36 (75.0)		52 (94.5)
Resistant	10 (90.9)		10 (100)
Amoxicillin		NA		NA
Susceptible	46 (78.0)		62 (95.4)
Resistant
Dual resistance		0.66		0.65
Present	5 (71.4)		4 (100)
Absent	41 (78.8)		58 (95.0)
Compliance		0.47		0.66
Good	66 (79.5)		78 (94.0)
Poor	2 (100)		3 (100)
Smoking		0.2		0.31
Present	6 (100)		14 (100)
Absent	62 (78.5)		67 (93.1)
Alcohol		0.29		0.21
Present	16 (88.9)		20 (100)
Absent	52 (77.6)		61 (92.4)
Gastroduodenal disease		0.91		0.57
Non-ulcer dyspepsia	43 (79.6)		38 (92.7)
Peptic ulcer	25 (80.6)		43 (95.6)
Bacterial density		0.31		0.4
Mild	4 (100)		7 (87.5)
Moderate/marked	64 (79.0)		74 (94.9)